The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
Open accessAbstract
BACKGROUND: Obesity and type 2 diabetes are prevalent in patients with heart failure with preserved ejection fraction and are characterized by a high symptom burden. No approved therapies specifically target obesity-related heart failure with preserved ejection fraction in persons with type 2 diabetes. METHODS: We randomly assigned patients who had heart failure with preserved ejection fraction, a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or more, and type 2 diabetes to receive once-weekly semaglutide (2.4 mg) or placebo for 52 weeks. The primary end points were the change from baseline in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating fewer symptoms and physical limitations) and the change in body weight. Confirmatory secondary end points included the change in 6-minute walk distance; a hierarchical composite end point that included death, heart failure events, and differences in the change in the KCCQ-CSS and 6-minute walk distance; and the change in the C-reactive protein (CRP) level. RESULTS: A total of 616 participants underwent randomization. The mean change in the KCCQ-CSS was 13.7 points with semaglutide and 6.4 points with placebo (estimated difference, 7.3 points; 95% confidence interval [CI], 4.1 to 10.4; P<0.001), and the mean percentage change in body weight was -9.8% with semaglutide and -3.4% with placebo (estimated difference, -6.4 percentage points; 95% CI, -7.6 to -5.2; P<0.001). The results for the confirmatory secondary end points favored semaglutide over placebo (estimated between-group difference in change in 6-minute walk distance, 14.3 m [95% CI, 3.7 to 24.9; P = 0.008]; win ratio for hierarchical composite end point, 1.58 [95% CI, 1.29 to 1.94; P<0.001]; and estimated treatment ratio for change in CRP level, 0.67 [95% CI, 0.55 to 0.80; P<0.001]). Serious adverse events were reported in 55 participants (17.7%) in the semaglutide group and 88 (28.8%) in the placebo group. CONCLUSIONS: Among patients with obesity-related heart failure with preserved ejection fraction and type 2 diabetes, semaglutide led to larger reductions in heart failure-related symptoms and physical limitations and greater weight loss than placebo at 1 year. (Funded by Novo Nordisk; STEP-HFpEF DM ClinicalTrials.gov number, NCT04916470.).
Overview
CoChat Summary
TL;DR
In the STEP-HFpEF DM trial, once-weekly semaglutide 2.4 mg improved heart failure–related symptoms and produced greater weight loss than placebo over 52 weeks in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes. Confirmatory secondary end points (6-minute walk distance, a hierarchical composite, and CRP) also favored semaglutide.
Key findings
- KCCQ-CSS mean change: 13.7 points with semaglutide vs 6.4 points with placebo (estimated difference 7.3 points; 95% CI 4.1 to 10.4; P<0.001).
- Mean percentage change in body weight: −9.8% with semaglutide vs −3.4% with placebo (estimated difference −6.4 percentage points; 95% CI −7.6 to −5.2; P<0.001).
- Confirmatory secondary end points favored semaglutide: 6-minute walk distance difference 14.3 m (95% CI 3.7 to 24.9; P=0.008); win ratio for the hierarchical composite 1.58 (95% CI 1.29 to 1.94; P<0.001); treatment ratio for CRP change 0.67 (95% CI 0.55 to 0.80; P<0.001).
- Serious adverse events occurred in 55 participants (17.7%) in the semaglutide group and 88 (28.8%) in the placebo group.
Methods
- Randomized, placebo-controlled trial: 616 participants with HFpEF, BMI ≥30, and type 2 diabetes were assigned to once-weekly semaglutide 2.4 mg or placebo for 52 weeks.
- Co-primary end points: change from baseline in KCCQ-CSS (0–100, higher = fewer symptoms/limitations) and change in body weight.
- Confirmatory secondary end points: change in 6-minute walk distance; a hierarchical composite of death, heart failure events, and differences in KCCQ-CSS and 6-minute walk distance change; and change in CRP level. (Funded by Novo Nordisk; NCT04916470.)
Limitations
- Not stated in the paper (the provided text is the abstract and bibliographic record; no limitations section is included).
- Evident from the text: the report covers a 52-week treatment period only, so durability beyond 1 year is not addressed; and the trial population is restricted to patients with HFpEF, BMI ≥30, and type 2 diabetes, limiting generalizability to other HFpEF or non-diabetic populations.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 0 Not valid · 0 Not checked · 7 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“estimated between-group difference in change in 6-min-ute walk distance, 14.3 m [95% CI, 3.7 to 24.9; P=0.008]”
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Serious adverse events were reported in 55 participants (17.7%) in the semaglutide group and 88 (28.8%) in the placebo group.”
plainn = 55- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The mean change in the KCCQ-CSS was 13.7 points with semaglutide and 6.4 points with placebo (estimated difference, 7.3 points; 95% confidence interval [CI], 4.1 to 10.4; P<0.001)”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“estimated treatment ratio for change in CRP level, 0.67 [95% CI, 0.55 to 0.80; P<0.001]”
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 2
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with HFpEF and obesity (with and without diabetes), semaglutide 2.4 mg once weekly for 52 weeks improved symptoms, physical function, exercise function and bodyweight compared to placebo (STEP HFpEF and STEP HFpEF DM clinical trials) [59,91].”
From Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? (2024) · cites this paper as [91]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“weight-loss interventions (eg, gastric bypass surgery and glucagon-like peptide-1 receptor agonists) can reduce the risk of incident HF and improve symptoms in patients with established HFpEF.16–20”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“After 1 year of treatment, the mean change in the score was 13.7 points with semaglutide and 6.4 points with placebo,”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [323]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and the mean body weight was reduced by 9.8% in the group assigned to semaglutide compared with 3.4% with placebo.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [323]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, in the confirmatory secondary end point, semaglutide treatment improved 6-min walk distance.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [323]
Experimental — accuracy not yet measured
14 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationEmpagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Self-citationSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Self-citationDapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206286 · Cited by 2,884
Self-citationMcDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad195 · Cited by 2,612
Self-citationGreen, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669
Self-citationDavies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Self-citationThe effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man.
DeFronzo, R. A., Cooke, C. R., Andres, R., Faloona, G. R., & Davis, P. J. (1975) · Journal of Clinical Investigation · doi:10.1172/jci107996 · Cited by 1,115
Cited by
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
Packer, M., Zile, M. R., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ge, J., Weerakkody, G. J., Ou, Y., Bunck, M. C., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2410027 · Cited by 1,009
Self-citationType 2 diabetes mellitus in adults: pathogenesis, prevention and therapy
Lu, X., Xie, Q., Pan, X., Zhang, R., Zhang, X., Peng, G., Zhang, Y., Shen, S., & Tong, N. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01951-9 · Cited by 665
“243 In the SURMOUNT-2 trial, GIP/GLP-1 RA tirzepatide demonstrated a greater weight loss of 14.7%; however, semaglutide and tirzepa-tide were both approximately 5% less effective in preobesity and obese people with T2D than in those without diabetes.”
BackgroundInfluential10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Das, S. R., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s010 · Cited by 486
Self-citationButler, J., Shah, S. J., Petrie, M. C., Borlaug, B. A., Abildstrøm, S. Z., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Verma, S., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00469-0 · Cited by 386
Self-citationEfficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383
Obesity and cardiovascular disease: An ESC clinical consensus statement
Koskinas, K. C., Van Craenenbroeck, E. M., Antoniades, C., Blüher, M., Gorter, T. M., Hanssen, H., Marx, N., McDonagh, T. A., Mingrone, G., Rosengren, A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae508 · Cited by 313
Kosiborod, M. N., Deanfield, J., Pratley, R., Borlaug, B. A., Butler, J., Davies, M. J., Emerson, S. S., Kahn, S. E., Kitzman, D. W., Lingvay, I., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01643-x · Cited by 308
Self-citationDeanfield, J., Verma, S., Scirica, B. M., Kahn, S. E., Emerson, S. S., Ryan, D., Lingvay, I., Colhoun, H. M., Plutzky, J., Kosiborod, M. N., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01498-3 · Cited by 275
Self-citationAmerican Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s008 · Cited by 236
GLP-1-based therapies for diabetes, obesity and beyond
Drucker, D. J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01183-8 · Cited by 236
“111,112).”
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s010 · Cited by 225
Diagnosis and Treatment of Type 2 Diabetes in Adults: A Review
Kalyani, R. R., Neumiller, J. J., Maruthur, N. M., & Wexler, D. J. (2025) · JAMA · doi:10.1001/jama.2025.5956 · Cited by 204
Beghini, A., Sammartino, A. M., Papp, Z., von Haehling, S., Biegus, J., Ponikowski, P., Adamo, M., Falco, L., Lombardi, C. M., Pagnesi, M., et al. (2025) · ESC Heart Failure · doi:10.1002/ehf2.14857 · Cited by 203
Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure
Kramer, C. M., Borlaug, B. A., Zile, M. R., Ruff, D., DiMaria, J. M., Menon, V., Ou, Y., Zarante, A. M., Hurt, K. C., Murakami, M., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.11.001 · Cited by 200
Self-citationJCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E., Sato, K., Teramoto, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Circulation Journal · doi:10.1253/circj.cj-25-0002 · Cited by 191
9. pharmacologic approaches to glycemic treatment: standards of care in diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s009 · Cited by 263
Borlaug, B. A., Zile, M. R., Kramer, C. M., Baum, S. J., Hurt, K., Litwin, S. E., Murakami, M., Ou, Y., Upadhyay, N., & Packer, M. (2025) · Nature Medicine · doi:10.1038/s41591-024-03374-z · Cited by 166
“These results are consistent with findings observed in the STEP-HFpEF program, where the glucagon-like peptide receptor-1 agonist semaglutide was also shown to improve health status and exercise capacity 20,21 .”
Self-citationInflammation and Cardiovascular Disease: 2025 ACC Scientific Statement
Mensah, G. A., Arnold, N., Prabhu, S. D., Ridker, P. M., & Welty, F. K. (2025) · JACC · doi:10.1016/j.jacc.2025.08.047 · Cited by 177
Rivera, F. B., Cruz, L. L. A., Magalong, J. V., Ruyeras, J. M. M., Aparece, J. P., Bantayan, N. R. B., Lara-Breitinger, K. M., & Gulati, M. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100679 · Cited by 181
“…Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes) trial demonstrated that among patients with heart failure with preserved ejection fraction, obesity treat-ment with semaglutide led to reduced symptoms, limitations, and greater exercise function and weight loss [8,9].”
BackgroundInfluentialSolomon, S. D., Ostrominski, J. W., Wang, X., Shah, S. J., Borlaug, B. A., Butler, J., Davies, M. J., Kitzman, D. W., Verma, S., Abildstrøm, S. Z., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.08.021 · Cited by 154
Self-citationPratley, R. E., Tuttle, K. R., Rossing, P., Rasmussen, S., Perkovic, V., Nielsen, O. W., Mann, J. F. E., MacIsaac, R. J., Kosiborod, M. N., Kamenov, Z., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.08.004 · Cited by 132
Self-citationTransforming obesity: The advancement of multi-receptor drugs
Kusminski, C. M., Perez-Tilve, D., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Scherer, P. E. (2024) · Cell · doi:10.1016/j.cell.2024.06.003 · Cited by 126
Theodorakis, N., & Nikolaou, M. (2025) · Biomolecules · doi:10.3390/biom15020213 · Cited by 174
Obesity and cardiovascular disease: an ESC clinical consensus statement
Koskinas, K. C., Craenenbroeck, E. M. V., Antoniades, C. A., Blüher, M., Gorter, T. M., Hanssen, H., Marx, N., McDonagh, T. A., Mingrone, G., Rosengren, A., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae279 · Cited by 146
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
Inflammation in Obesity-Related HFpEF
Verma, S., Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Kitzman, D. W., Shah, S. J., Rönnbäck, C., Abildstrom, S. Z., Liisberg, K., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.08.028 · Cited by 121
Self-citationSemaglutide and NT-proBNP in Obesity-Related HFpEF
Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Kitzman, D. W., Shah, S. J., Verma, S., Jensen, T. J., Einfeldt, M. N., Liisberg, K., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.04.022 · Cited by 95
Self-citationMcGowan, B., Ciudin, A., Baker, J. L., Busetto, L., Dicker, D., Frühbeck, G., Goossens, G. H., Monami, M., Sbraccia, P., Martinez-Tellez, B., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03978-z · Cited by 100
Shah, S. J., Sharma, K., Borlaug, B. A., Butler, J., Davies, M., Kitzman, D. W., Petrie, M. C., Verma, S., Patel, S., Chinnakondepalli, K. M., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae322 · Cited by 94
Self-citationSeferovic, P. M., Paulus, W. J., Rosano, G., Polovina, M. M., Petrie, M. C., Jhund, P. S., Tschöpe, C., Sattar, N. A., Piepoli, M. F., Papp, Z. L., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3347 · Cited by 141
Self-citationCardiovascular Effects and Tolerability of GLP-1 Receptor Agonists
Galli, M., Benenati, S., Laudani, C., Simeone, B., Sarto, G., Ortega‐Paz, L., Rocco, E., Bernardi, M., Spadafora, L., D’Amario, D., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.027 · Cited by 128
Inflammatory Trajectory of Type 2 Diabetes: Novel Opportunities for Early and Late Treatment
Pellegrini, V., Grotta, R. L., Carreras, F., Giuliani, A., Sabbatinelli, J., Olivieri, F., Berra, C., Ceriello, A., & Prattichizzo, F. (2024) · Cells · doi:10.3390/cells13191662 · Cited by 117
Proteomic changes upon treatment with semaglutide in individuals with obesity
Maretty, L., Gill, D., Simonsen, L., Soh, K., Zagkos, L., Galanakis, M., Sibbesen, J., Iglesias, M. T., Secher, A., Valkenborg, D., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03355-2 · Cited by 86
“Indeed, data from STEP-HFpEF and STEP-HFpEF DM trials have shown a significant reduction in inflammatory markers such as CRP with semaglutide compared with placebo 45,46 .”
Heart Failure with Preserved Ejection Fraction
Cannata, A. N., & McDonagh, T. A. (2025) · New England Journal of Medicine · doi:10.1056/nejmcp2305181 · Cited by 96
Diabetes and its complications: molecular mechanisms, prevention and treatment
Zhao, L., Yuan, J., Yang, Q., Ma, J., Yang, F., Zou, Y., Liu, K., & Liu, F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02401-w · Cited by 80
“The fi ndings of meta-analyses and clinical trials indicate that semaglutide not only reduces the risk of MACE and heart failure 300,301 but also improves renal outcomes in obese patients with or without diabetes.”
2025 ACC Scientific Statement on the Management of Obesity in Adults With Heart Failure
Kittleson, M. M., Benjamin, E. J., Blumer, V., Harrington, J., Januzzi, J. L., McMurray, J. J. V., & Vest, A. R. (2025) · JACC · doi:10.1016/j.jacc.2025.05.008 · Cited by 79
Zile, M. R., Borlaug, B. A., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ou, Y., Weerakkody, G. J., Hurt, K. C., Kanu, C., et al. (2025) · Circulation · doi:10.1161/circulationaha.124.072679 · Cited by 74
Self-citationObesity accelerates cardiovascular ageing
Ruperez, C., Madeo, F., de Cabo, R., Kroemer, G., & Abdellatif, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf216 · Cited by 73
“214,255 Mechanistically, GLP-1RAs have systemic anti-inflammatory, anti-hypertensive, and lipid-lowering properties that contribute to their beneficial cardiovascular effects.”
Wang, W., Volkow, N. D., Berger, N. A., Davis, P. B., Kaelber, D. C., & Xu, R. (2024) · Annals of Internal Medicine · doi:10.7326/m23-2718 · Cited by 72
Reddy, Y. N. V., Tada, A., Obokata, M., Carter, R. E., Kaye, D. M., Handoko, M. L., Andersen, M. J., Sharma, K., Tedford, R. J., Redfield, M. M., et al. (2025) · Circulation · doi:10.1161/circulationaha.124.072156 · Cited by 82
Self-citationISPAD Clinical Practice Consensus Guidelines 2024: Type 2 Diabetes in Children and Adolescents
SHAH, A. S., Pérez, M. B., CHANG, N. T., Fu, J., Hannon, T. S., Kelsey, M. M., Peña, A. S., Pinhas‐Hamiel, O., Urakami, T., Wicklow, B. A., et al. (2024) · Hormone Research in Paediatrics · doi:10.1159/000543033 · Cited by 97
Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction
Krüger, N., Schneeweiss, S., Fuse, K., Matseyko, S., Sreedhara, S. K., Hahn, G., Schunkert, H., & Wang, S. V. (2025) · JAMA · doi:10.1001/jama.2025.14092 · Cited by 66
Trends in Glucagon-Like Peptide 1 Receptor Agonist Prescribing Patterns
(2025) · The American Journal of Managed Care · doi:10.37765/ajmc.2025.89778 · Cited by 65
Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction
Verma, S., Butler, J., Borlaug, B. A., Davies, M. J., Kitzman, D. W., Shah, S. J., Petrie, M. C., Barros, E., Rönnbäck, C., Vestergaard, L. S., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.06.001 · Cited by 80
Self-citationWAQAS, S. A., Sohail, M. U., Saad, M., Minhas, A. M. K., Greene, S. J., Fudim, M., Fonarow, G. C., Abramov, D., Khan, M. S., & Ahmed, R. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.01.022 · Cited by 73
Mutruc, V., Bologa, C., Șorodoc, V., Ceasovschih, A., Morărașu, B. C., Șorodoc, L., Catar, O., & Lionte, C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082833 · Cited by 88
“…trials (i.e., STEP-HFpEF and STEP-HFpEF DM) and the FLOW (patients with T2D and CKD) and SELECT (patients post ASCVD or peripheral arterial disease) trials showed that relative to placebo, semaglutide reduced the risk of the combined endpoint of cardiovascular death or HF by 31% [6,104,105].”
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s008 · Cited by 160
Schou, M., Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Kitzman, D. W., Shah, S. J., Verma, S., Patel, S., Chinnakondepalli, K., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.04.038 · Cited by 70
Self-citationNdumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Old, V. J., Davies, M. J., Papamargaritis, D., Choudhary, P., & Watson, E. L. (2025) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.13677 · Cited by 55
Self-citationBae, J. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0220 · Cited by 98
“…Preserved Ejection Fraction and Diabetes Mellitus (STEP-HFpEF DM) trial demonstrated that semaglutide significantly reduced body weight and improved HF-related symptoms and physical limitations in people with obesity-related HF with preserved ejection fraction and type 2 diabetes mellitus [93].”
Stolfo, D., Iacoviello, M., Chioncel, O. D., Anker, M. S., Bayés‐Genís, A., Braunschweig, F., Cannata, A. N., Hadidi, S. E., Filippatos, G., Jhund, P. S., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3642 · Cited by 59
Targeting organ-specific mitochondrial dysfunction to improve biological aging
Madreiter‐Sokolowski, C. T., Hiden, U., Krstić, J., Panzitt, K., Wagner, M., Enzinger, C., Khalil, M., Abdellatif, M., Malle, E., Madl, T., et al. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108710 · Cited by 59
Bonfioli, G. B., Rodella, L., Metra, M., & Vizzardi, E. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10450-6 · Cited by 64
GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms
Mullur, N., Morissette, A., Morrow, N. M., & Mulvihill, E. E. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0046 · Cited by 51
Mechano-energetic uncoupling in heart failure
Aksentijević, D., Sedej, S., Fauconnier, J., Paillard, M., Abdellatif, M., Streckfuß‐Bömeke, K., Ventura‐Clapier, R., van der Velden, J., de Boer, R. A., Bertero, E., et al. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01167-6 · Cited by 60
“…flux from fatty acids towards glucose oxidation proved to be unsuccessful in improving outcomes 16 , important breakthroughs have been made in metabolic treatments for HF with sodium–glucose cotransporter 2 (SGLT2) inhibitors 17–20 and glucagon-like peptide 1 (GLP1) receptor agonists 21–24 .”
Finerenone, Obesity, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction
Butt, J. H., Henderson, A. D., Jhund, P. S., Claggett, B. L., Desai, A. S., Lay‐Flurrie, J., Viswanathan, P., Lage, A. Z., Scheerer, M. F., Lam, C. S. P., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.10.111 · Cited by 56
Self-citationSilverii, G. A., Pala, L., Cresci, B., & Mannucci, E. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16076 · Cited by 49
Packer, M., Zile, M. R., Kramer, C. M., Murakami, M., Ou, Y., & Borlaug, B. A. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.009 · Cited by 49
Self-citationVerma, S., Butler, J., Borlaug, B. A., Davies, M. J., Kitzman, D. W., Petrie, M. C., Shah, S. J., Jensen, T. J., Rasmussen, S., Rönnbäck, C., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.08.023 · Cited by 52
Self-citationDiscovery of Titin and Its Role in Heart Function and Disease
Granzier, H. L. M., & Labeit, S. (2025) · Circulation Research · doi:10.1161/circresaha.124.323051 · Cited by 56
Zafer, M., Tavaglione, F., Romero‐Gómez, M., & Loomba, R. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70196 · Cited by 47
Associations between Class I, II, or III Obesity and Health Outcomes
Yao, Z., Tchang, B. G., Albert, M. H., Blumenthal, R. S., Nasir, K., & Blaha, M. J. (2025) · NEJM Evidence · doi:10.1056/evidoa2400229 · Cited by 57
Carbone, F., Després, J., Ioannidis, J. P. A., Neeland, I. J., Garruti, G., Busetto, L., Liberale, L., Ministrini, S., Vilahur, G., Schindler, T. H., et al. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70059 · Cited by 55
Savarese, G., Schiattarella, G. G., Lindberg, F., Anker, M. S., Bayés‐Genís, A., Bäck, M., Braunschweig, F., Bucciarelli‐Ducci, C., Butler, J., Cannata, A. N., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3676 · Cited by 56
Self-citationSawami, K., Tanaka, A., & Node, K. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02500-y · Cited by 56
“Similar results were reported in STEP-HFpEF DM, which included patients with diabetes excluded in STEP-HFpEF [30].”
Sattar, N. A., & Lee, M. M. Y. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00363-2 · Cited by 57
Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity
Lin, H.-T., Tsai, Y.-F., Liao, P.-L., & Wei, J. C.-C. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.21016 · Cited by 43
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E. T., Sato, K., TERAMOTO, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.02.014 · Cited by 67
Cesaro, A., Pastori, D., Acerbo, V., Biccirè, F. G., Golino, M., Panico, D., Prati, F., Abbate, A., Lip, G. Y. H., & Calabrò, P. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf257 · Cited by 55
Metabolic rewiring and inter-organ crosstalk in diabetic HFpEF
Luo, L., Zuo, Y., & Dai, L. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02707-7 · Cited by 56
“Similarly, the STEP-HFpEF DM trial demonstrated that semaglutide reduced symptoms and physical limitations while achieving weight loss in individuals with obesity-related HFpEF and concomitant T2DM [138].”
Theodorakis, N., & Nikolaou, M. (2025) · Biomedicines · doi:10.3390/biomedicines13010135 · Cited by 50
Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease
Schwabe, R. F., Tacke, F., Sugimoto, A., & Friedman, S. L. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101421 · Cited by 70
Reddy, Y. N. V., Frantz, R. P., Hemnes, A. R., Hassoun, P. M., Horn, E. M., Leopold, J. A., Rischard, F. P., Rosenzweig, E. B., Hill, N. S., ERZURUM, S. C., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.530 · Cited by 45
Self-citationSemaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment
Salvador, R., Moutinho, C. M. S. G., Sousa, C., Vinha, A. F., Carvalho, M. C., & Matos, C. M. (2025) · Pharmaceuticals · doi:10.3390/ph18030399 · Cited by 55
Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis
Natividade, G. R., Spiazzi, B. F., Baumgarten, M. W., Bassotto, C., Pereira, A. A., Fraga, B. L., Scalco, B. G., Mattes, N. R., Lavinsky, D., Kramer, C. K., et al. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2025.2489 · Cited by 41
Madsbad, S., & Holst, J. J. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2472408 · Cited by 43
“In another trial in people with obesity, heart failure with preserved ejection fraction and type 2 diabetes, semaglutide 2.4 mg or placebo for 52-weeks improved heart-failure-related symptoms and physical limitations [49].”
InfluentialGregson, J., Taylor, D., Owen, R., Collier, T. J., Cohen, D. J., & Pocock, S. (2025) · Circulation · doi:10.1161/circulationaha.124.070251 · Cited by 45
Ndumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 145
Abdin, A., Böhm, M., Shahim, B., Karlström, P., Kulenthiran, S., Skouri, H. N., & Lund, L. H. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132304 · Cited by 52
Lassen, M. C. H., Johansen, N. D., Modin, D., Catarig, A., Vistisen, B. K., Amadid, H., Zimmermann, E., Gislason, G., & Biering‐Sørensen, T. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15872 · Cited by 40
Hosseinpour, A., Sood, A., Kamalpour, J., Zandi, E., Pakmehr, S., Hosseinpour, H., Sood, A., Agrawal, A., & Gupta, R. (2024) · Clinical Cardiology · doi:10.1002/clc.24314 · Cited by 40
Obesity and Weight Loss Strategies for Patients With Heart Failure
Vest, A. R., Schauer, P. R., Rodgers, J. E., Sanderson, E., LaChute, C., Seltz, J., Lavie, C. J., Mandras, S. A., Tang, W. H. W., & daSilva‐deAbreu, A. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.06.006 · Cited by 47
Karakasis, P., Fragakis, N., Patoulias, D., Theofilis, P., Sagris, Μ., Koufakis, T., Vlachakis, P. K., Rangraze, I. R., El‐Tanani, M., Tsioufis, K. P., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12092112 · Cited by 40
“…also favored semaglutide, with improvements in 6MWD (14.3 m; 95% CI 3.7–24.9; p = 0.008), a higher win ratio for the hierarchical composite endpoint (1.58; 95% CI 1.29–1.94; p < 0.001), and a greater reduction in CRP levels (estimated treatment ratio, 0.67; 95% CI 0.55–0.80; p < 0.001) [94].”
BackgroundMethodInfluentialSurvodutide for the Treatment of Obesity
Kosiborod, M., Platz, E., Wharton, S., le Roux, C. W., Brueckmann, M., Hussain, S. A., Unseld, A., Startseva, E., & Kaplan, L. M. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.09.004 · Cited by 41
Self-citationWharton, S., le Roux, C. W., Kosiborod, M., Platz, E., Brueckmann, M., Jastreboff, A. M., Hussain, S. A., Pedersen, S. D., Borowska, L., Unseld, A., et al. (2024) · Obesity · doi:10.1002/oby.24184 · Cited by 46
Self-citationNew drugs for the treatment of obesity: do we need approaches to preserve muscle mass?
Ryan, D. H. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09967-4 · Cited by 34
“In addition to glycemic and weight loss efficacy, for patients with obesity with or without diabetes, benefits are seen in heart failure with preserved ejection fraction (HFpEF) with semaglutide [8–10] and tirzepatide [11].”
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf036 · Cited by 40
Neves, J. S., Leite, A. R., Mentz, R. J., Holman, R. R., Zannad, F. M., Butler, J., Packer, M., & Ferreira, J. P. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3478 · Cited by 40
Self-citationKarakasis, P., Vlachos, K. G., Antoniadis, A. P., Siontis, K. C., Patoulias, D., Fragakis, N., & Mantzoros, C. S. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156463 · Cited by 51
Safety and Effectiveness of Glucagon-like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease
Anderson, S. R., Ayoub, M., Coats, S., Mchenry, S. A., Tan, T., & Deepak, P. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003208 · Cited by 37
Gogineni, P., Melson, E., Papamargaritis, D., & Davies, M. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2356254 · Cited by 32
“For people without diabetes, the mean WL with semaglutide 2.4 mg once weekly at 52 weeks was 13.3% (vs 2.6% WL with placebo, STEP HFpEF trial), when for people with T2D mean WL with semaglutide 2.4 mg was 9.8% (vs 3.6% WL with placebo, STEP HFpEF DM trial) [59,91].”
BackgroundMethodInfluentialSelf-citationEmerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025)
Patel, S., & Niazi, S. K. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17081036 · Cited by 48
GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies
Yang, H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14196758 · Cited by 46
“Patients with obese HFpEF who had T2DM or not received treatment with GLP-1 agonists in STEP-HFpEF trials which showed KCCQ score improvements of +16.6 points and weight loss of 13% and reduced HF hospitalization rates by 79% [11,56].”
InfluentialCleto, A. S., Schirlo, J. M., Beltrame, M. L., Gomes, V. H. O., Acras, I. H., Neiverth, G. S., da Silva, B. B., Juliatto, B. M. S., Machozeki, J., & Martins, C. M. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01646-9 · Cited by 37
“Therefore, despite this limitation, there was no difference in the result.”
Davies, M. J., van der Meer, P., Verma, S., Patel, S., Chinnakondepalli, K. M., Borlaug, B. A., Butler, J., Kitzman, D. W., Shah, S. J., Harring, S., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00304-8 · Cited by 32
Self-citationPacker, M., Zile, M. R., Kramer, C. M., DiMaria, J. M., Baum, S. J., Litwin, S. E., Murakami, M., Zhou, C., Ou, Y., Koeneman, L., et al. (2025) · JACC · doi:10.1016/j.jacc.2025.06.058 · Cited by 34
Self-citationTreating sarcopenic obesity in the era of incretin therapies: perspectives and challenges
Chen, A. S., & Batsis, J. A. (2025) · Diabetes · doi:10.2337/dbi25-0004 · Cited by 32
Zhang, X., Cao, C., Zheng, F., Liu, C., & Tian, X. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07670-9 · Cited by 27
“In HF with preserved ejection fraction (HFpEF), GLP-1 RAs may not reduce HF hospitalization but might lower atherosclerotic event risks [66, 67].”
Early combination therapy with SGLT2i and GLP ‐1 RA or dual GIP / GLP ‐1 RA in type 2 diabetes
Vale, C., Lourenço, I. M., Jordan, G., Golovaty, I., Torres, H., Moin, T., Buysschaert, M., Neves, J. S., & Bergman, M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16077 · Cited by 33
Metadata
- Authors
- Kosiborod, M. N., Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Treppendahl, M. B., Verma, S., Jensen, T. J., Liisberg, K., Lindegaard, M. L., Abhayaratna, W., Ahmed, F. Z., Ben-Gal, T., Chopra, V., Ezekowitz, J. A., Fu, M., Ito, H., Lelonek, M., Melenovský, V., Merkely, B., Núñez, J., Perna, E., Schou, M., Senni, M., Sharma, K., van der Meer, P., Von Lewinski, D., Wolf, D., & Shah, S. J.
- Affiliations
- University of Copenhagen (DK)
- From the Department of Cardiovascular Disease, Saint Luke’s Mid America Heart Institute, University of Missouri–Kansas City School of Medicine, Kansas City (M.N.K.); the School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow (M.C.P.), the Diabetes Research Centre, University of Leicester, and the NIHR Leicester Biomedical Research Centre, Leicester (M.J.D.), and the Division of Cardiovascular Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester (F.Z.A.) — all in the United Kingdom; the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.); the Baylor Scott and White Research Institute, Dallas (J.B.); the Department of Medicine, University of Mississippi, Jackson (J.B.); Novo Nordisk, Søborg (G.K.H., D.V.M., M.B.T., T.J.J., K.L., M.L.L.), and the Department of Cardiology, Herlev-Gentofte Hospital, University of Copenhagen, Herlev (M. Schou) — both in Denmark; the Department of Cardiovascular Medicine and Section on Geriatrics an...
- ORCID
- Kosiborod, Mikhail N.
- Petrie, Mark C.
- Borlaug, Barry A.
- Butler, Javed
- Davies, Melanie J.
- Hovingh, G. Kees
- Kitzman, Dalane W.
- Verma, Subodh
- Abhayaratna, Walter
- Ahmed, Fozia Z.
- Chopra, Vijay
- Ezekowitz, Justin A.
- Fu, Michael
- Ito, Hiroshi
- Lelonek, Małgorzata
- Melenovský, Vojtěch
- Núñez, Julio
- Perna, Eduardo
- Schou, Morten
- Senni, Michele
- Sharma, Kavita
- Wolf, Dennis
- Shah, Sanjiv J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-04-18
- Volume
- 390
- Issue
- 15
- Pages
- 1394-1407
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4393255879
- Cited by
- 758
- References
- 35
- Citations by year
- 2026: 282 · 2025: 345 · 2024: 131
- FWCI
- 226.84
- Type
- journal article
- Language
- en
- Open access
- green
- pure.amsterdamumc.nl
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by-nc-nd)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- semaglutide, obesity, heart failure with preserved ejection fraction, type 2 diabetes, GLP-1 receptor agonists, weight loss, Kansas City Cardiomyopathy Questionnaire, 6-minute walk distance, C-reactive protein, heart failure events, body mass index, symptom burden, adverse events, drug safety
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Heart Failure, Humans, Obesity, Stroke Volume
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.